ClinicalTrials.gg
Not yet recruitingNCT06953570Updated May 1, 2025

Impact of Frailty on Nalbuphine Dose for Postoperative Analgesia in Elderly Patients Undergoing Laparoscopic GI Surgery

An observational study in PCIA, Frailty and Laparoscopic Gastrointestinal Surgery, sponsored by Yongtao Sun. Not yet recruiting. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2025-05-01.

Sponsored by Yongtao Sun · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
120
Ages
65 Years and older
Sex
All
01

Study summary

This study aims to investigate the ED50 and ED95 of nalbuphine combined with dexmedetomidine in patient-controlled intravenous analgesia (PCIA) for elderly patients with different degrees of frailty, as well as their analgesic effects and complications. The results of this study can provide safe and effective dosage guidance for postoperative analgesia in frail patients, help optimize analgesic regimens, reduce the risk of complications, and improve the quality of postoperative recovery.

Read the detailed description

With the increasing aging of the population in China, the proportion of elderly patients in the surgical population is continuously rising, with elderly frail patients accounting for as high as 25-50%. Previous studies have shown that postoperative pain management in elderly frail patients is associated with four major issues:

  1. Enhanced pain perception.
  2. Decreased pain tolerance.
  3. Changes in pharmacokinetics and pharmacodynamics.
  4. Iatrogenic titration patterns.

Patient-controlled intravenous analgesia (PCIA) is one of the most commonly used analgesic methods, which can shorten hospital stays, reduce the incidence of perioperative complications, and improve quality of life. However, elderly patients are more prone to hypotension, nausea, and vomiting, necessitating additional antiemetics and rescue analgesics. Nalbuphine, a dual-acting drug as a κ-receptor agonist and μ-receptor antagonist, has analgesic potency comparable to morphine and a longer duration of action (3-6 hours). However, studies have shown that due to reduced liver and kidney function, the metabolism of Nalbuphine is prolonged in elderly frail patients. Dexmedetomidine, a highly selective α2-receptor agonist with sedative, analgesic, anxiolytic, and sympatholytic properties, can reduce postoperative cardiovascular complications, enhance opioid analgesia, and lower the incidence of postoperative delirium, making it an ideal choice for multimodal analgesia. However, no studies have yet explored the dose-response relationship of dexmedetomidine combined with Nalbuphine in elderly frail patients, especially the impact of different degrees of frailty (such as mFI classification) on the median effective dose (ED50) of Nalbuphine.

This study, for the first time, employs the modified Dixon up-and-down sequential method to systematically evaluate the influence of different degrees of frailty on the ED50 of Nalbuphine-dexmedetomidine combination analgesia in elderly patients undergoing laparoscopic gastrointestinal surgery, and to analyze its analgesic effects and complication risks. The results of this study will provide evidence-based guidance for precise pain management in frail patients and promote the application of Enhanced Recovery After Surgery (ERAS) principles in the elderly frail population.

02

Conditions studied

  • PCIA
  • Frailty
  • Laparoscopic Gastrointestinal Surgery

Browse trials for

Keywords

  • nalbuphine
  • ED50
  • PCIA
  • laparoscopic gastrointestinal surgery
  • frailty
03

In context

Frailty

1,291 studies on the registry are indexed under Frailty; 454 are open to participants now.

This study's planned enrollment of 120 is below the median of 225 across 495 observational studies indexed under Frailty.

Browse Frailty studies →

Lead sponsor

Yongtao Sun is the lead sponsor of 7 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Elderly patients undergoing laparoscopic gastrointestinal surgery

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who plan to undergo elective gastrointestinal surgery and are expected to stay in hospital for ≥3 days after surgery [except abdominal perineal combined with radical resection of rectal cancer (MILES)];
  2. I-Ⅳ;
  3. Age ≥65 years (2);
  4. 18.5 kg/m²≤\<30 kg/m²;
  5. Sign the form.

Exclusion criteria

Exclusion Criteria:

  1. Severe cardiopulmonary, liver, kidney and coagulation dysfunction
  2. Chemotherapy and radiotherapy were administered 1 month before surgery, and sedatives, antiemetic or antipruritic drugs were administered 24 hours before surgery
  3. History of drug abuse, chronic pain, mental illness, or allergy to the drugs used in this study
  4. Plan postoperative intubation or transfer to ICU;
  5. Participated in other clinical studies within the past 3 months.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
120 participants (estimated)
Patient registry
No

Groups and cohorts

  • frailty group(F)(mFI≧0.27)

    The initial PCA pump formulation for the first patient was set as: dexmedetomidine 2 μg/kg, nalbuphine 1 mg/kg, ondansetron 16 mg, diluted to 100 ml with normal saline. The study employed a modified Dixon up-and-down sequential method, with an initial dose of nalbuphine at 1 mg/kg. A resting Visual Analog Scale (VAS) score \> 3 within 24 hours postoperatively was defined as a negative response. If a negative response occurred, the dose of nalbuphine for the next patient in the same group would be increased by 0.1 mg/kg (e.g., 1.0 → 1.1 mg/kg). Conversely, if a positive response occurred, the dose for the next patient would be decreased by 0.1 mg/kg (e.g., 1.0 → 0.9 mg/kg). The trial was terminated when eight consecutive negative-to-positive inflection points were observed.

  • pre-frailty group (P)(0<mFI<0.27)

    The initial PCA pump formulation for the first patient was set as: dexmedetomidine 2 μg/kg, nalbuphine 1 mg/kg, ondansetron 16 mg, diluted to 100 ml with normal saline. The study employed a modified Dixon up-and-down sequential method, with an initial dose of nalbuphine at 1 mg/kg. A resting Visual Analog Scale (VAS) score \> 3 within 24 hours postoperatively was defined as a negative response. If a negative response occurred, the dose of nalbuphine for the next patient in the same group would be increased by 0.1 mg/kg (e.g., 1.0 → 1.1 mg/kg). Conversely, if a positive response occurred, the dose for the next patient would be decreased by 0.1 mg/kg (e.g., 1.0 → 0.9 mg/kg). The trial was terminated when eight consecutive negative-to-positive inflection points were observed.

  • non-frailty group (N)(mFI=0)

    The initial PCA pump formulation for the first patient was set as: dexmedetomidine 2 μg/kg, nalbuphine 1 mg/kg, ondansetron 16 mg, diluted to 100 ml with normal saline. The study employed a modified Dixon up-and-down sequential method, with an initial dose of nalbuphine at 1 mg/kg. A resting Visual Analog Scale (VAS) score \> 3 within 24 hours postoperatively was defined as a negative response. If a negative response occurred, the dose of nalbuphine for the next patient in the same group would be increased by 0.1 mg/kg (e.g., 1.0 → 1.1 mg/kg). Conversely, if a positive response occurred, the dose for the next patient would be decreased by 0.1 mg/kg (e.g., 1.0 → 0.9 mg/kg). The trial was terminated when eight consecutive negative-to-positive inflection points were observed.

06

What researchers measure

Primary outcomes

  1. Median Effective Dose (ED50) of Nalbuphine Based on Visual Analogue Scale (VAS) for Resting Pain at 24 Hours After Surgery

    The median effective dose (ED50) of nalbuphine is defined as the dose at which 50% of patients report a resting Visual Analogue Scale (VAS) pain score of ≤3 within 24 hours postoperatively. The VAS is a 10-cm line scale ranging from 0 (no pain) to 10 (worst imaginable pain), evaluated at rest.

    Time frame: Within 24 hours after the end of surgery

Secondary outcomes

  1. Dose of Nalbuphine Required to Achieve Resting VAS ≤3 in 95% of Patients Within 24 Hours After Surgery (ED95)

    The 95% effective dose (ED95) of nalbuphine is defined as the dose at which 95% of patients report a resting pain score of ≤3 on the Visual Analogue Scale (VAS) within 24 hours after laparoscopic gastrointestinal surgery. The VAS is a 10-cm horizontal line scale from 0 (no pain) to 10 (worst pain imaginable), evaluated in a supine resting state

    Time frame: Within 24 hours after the end of surgery

  2. Resting/Moving VAS (VASR/ VASM)

    The VAS is assessed at rest and during moving (coughing or changing position from back to side in bed). The pain degree was assessed with a 10cm scale (0-10 points) : 0 was no pain; A score below 3 indicates mild pain, which the patient can tolerate; 4-6 patients pain and affect sleep, can still tolerate; 7-10 points patients have gradually intense pain, the pain is unbearable.

    Time frame: At PACU discharge (immediately after anesthesia recovery), and at 6, 12, 18, 24, 36, and 48 hours after the end of surgery

  3. Ramsay Sedation Score (RASS)

    1 awake, patient anxious, restless or irritable; 2 points awake, patient cooperation, good orientation or quiet; At 3 points of wakefulness, the patient only responds to commands; 4 minutes sleep, patients respond quickly to tapping eyebrow or Johnson stimulation; 5 minutes sleep, the patient is slow to tap eyebrow or Johnson stimulation; 6 minutes of sleep, the person did not respond to tapping the eyebrow or Johnson stimulation.

    Time frame: At PACU discharge (immediately after anesthesia recovery), and at 6, 12, 18, 24, 36, and 48 hours after the end of surgery

  4. Brinell comfort Scale (BCS)

    0 is persistent pain; 1 is painless at rest, severe pain when breathing deeply or coughing; 2 are painless at rest, mild pain when breathing deeply or coughing; There was no pain during 3 minutes of quiet and deep breathing. 4 points: No pain when coughing.

    Time frame: At PACU discharge (immediately after anesthesia recovery), and at 6, 12, 18, 24, 36, and 48 hours after the end of surgery

  5. Nausea and vomiting (PONV)

    Nausea is an uncomfortable feeling of wanting to vomit, but there is no contractive movement of the abdominal muscles, diaphragm muscles, etc. Vomiting refers to the contraction of the diaphragm, chest muscles and abdominal wall muscles, which may be accompanied by vomiting of stomach contents, including dry heaving. If the vomiting events are more than 1 minute apart, they are considered separate episodes. 0 degree indicates no nausea or vomiting. Grade I is nausea and no vomiting; Grade Ⅱ was nausea with mild vomiting; Degree III is severe vomiting requiring further treatment; Grade IV is vomiting that is difficult to control.

    Time frame: At PACU discharge (immediately after anesthesia recovery), and at 6, 12, 18, 24, 36, and 48 hours after the end of surgery

  6. the effective pressing number of PCIA

    The effective number of PCIA compressions performed by the patient after surgery

    Time frame: At PACU discharge (immediately after anesthesia recovery), and at 6, 12, 18, 24, 36, and 48 hours after the end of surgery

  7. the cumulative pressing number of PCIA

    The total number of postoperatively applied PCIA

    Time frame: At PACU discharge (immediately after anesthesia recovery), and at 6, 12, 18, 24, 36, and 48 hours after the end of surgery

  8. sufentanil dose

    rescue sufentanil doses in PACU

    Time frame: Exiting PACU immediately

  9. Time to recovery

    length of stay in PACU

    Time frame: Exiting PACU immediately

  10. Postoperative Functional Recovery Milestones at Hospital Discharge

    Functional recovery is defined as the ability of the patient to (1) independently get out of bed, (2) walk at least 10 meters with or without assistance, (3) tolerate oral intake (clear fluids or diet), and (4) urinate spontaneously. Recovery is assessed using a standardized checklist by the attending physician or nurse prior to discharge.

    Time frame: At hospital discharge, typically within 3 to 7 days after surgery

  11. Rescue Analgesic Requirements Within 48 Hours After Surgery

    Number of additional doses of rescue analgesics administered to the patient within the first 48 hours postoperatively, recorded by nursing staff

    Time frame: At 6, 12, 18, 24, 36, and 48 hours after the end of surgery

  12. Systolic Blood Pressure (SBP) Within 48 Hours After Surgery

    SBP will be measured using automated patient monitors at predefined time points. The values will be recorded and analyzed as a continuous variable.

    Time frame: At PACU discharge, and at 6, 12, 18, 24, 36, and 48 hours after surgery

  13. Number of Participants Experiencing Respiratory Depression (RR <8/min or SpO₂ ≤90%) After Surgery

    Respiratory depression is defined as a respiratory rate \<8 breaths per minute or an oxygen saturation (SpO₂) ≤90% on room air. The incidence will be recorded at each predefined time point by nursing staff using bedside monitors

    Time frame: At PACU discharge (immediately after anesthesia recovery), and at 6, 12, 18, 24, 36, and 48 hours after the end of surgery

  14. Number of Participants Requiring Antipruritic Medication for Persistent Itching After Surgery

    Pruritus is defined as persistent itching that leads to administration of antipruritic medication (e.g., antihistamines or corticosteroids). The number of participants requiring such medications at each time point will be recorded by medical staff.

    Time frame: At PACU discharge (immediately after anesthesia recovery), and at 6, 12, 18, 24, 36, and 48 hours after the end of surgery

  15. Diastolic Blood Pressure (DBP) Within 48 Hours After Surgery

    DBP will be measured using automated patient monitors at predefined time points. The values will be recorded and analyzed as a continuous variable.

    Time frame: At PACU discharge, and at 6, 12, 18, 24, 36, and 48 hours after surgery

  16. Mean Arterial Pressure (MAP) Within 48 Hours After Surgery

    MAP will be measured using automated patient monitors at each specified time point. MAP is calculated using the formula: (SBP + 2 × DBP) / 3.

    Time frame: At PACU discharge, and at 6, 12, 18, 24, 36, and 48 hours after surgery

  17. Heart Rate (HR) Within 48 Hours After Surgery

    Heart rate will be measured using automated patient monitors. The values will be recorded in beats per minute (bpm) and analyzed continuously over time.

    Time frame: At PACU discharge, and at 6, 12, 18, 24, 36, and 48 hours after surgery

  18. Peripheral Oxygen Saturation (SpO₂) Within 48 Hours After Surgery

    SpO₂ will be recorded using pulse oximetry. Oxygen saturation (%) will be continuously monitored and recorded at predefined intervals.

    Time frame: At PACU discharge, and at 6, 12, 18, 24, 36, and 48 hours after surgery

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Helme RD, Meliala A, Gibson SJ. Methodologic factors which contribute to variations in experimental pain threshold reported for older people. Neurosci Lett. 2004 May 6;361(1-3):144-6. doi: 10.1016/j.neulet.2003.12.014. PubMed 15135914 ↗
  • Schofield PA. The assessment and management of peri-operative pain in older adults. Anaesthesia. 2014 Jan;69 Suppl 1:54-60. doi: 10.1111/anae.12520. PubMed 24303861 ↗
  • Joshi GP. Multimodal analgesia techniques and postoperative rehabilitation. Anesthesiol Clin North Am. 2005 Mar;23(1):185-202. doi: 10.1016/j.atc.2004.11.010. PubMed 15763418 ↗
  • Yeh YC, Lin TF, Lin FS, Wang YP, Lin CJ, Sun WZ. Combination of opioid agonist and agonist-antagonist: patient-controlled analgesia requirement and adverse events among different-ratio morphine and nalbuphine admixtures for postoperative pain. Br J Anaesth. 2008 Oct;101(4):542-8. doi: 10.1093/bja/aen213. Epub 2008 Jul 17. PubMed 18640992 ↗
  • Pasternak GW. Molecular biology of opioid analgesia. J Pain Symptom Manage. 2005 May;29(5 Suppl):S2-9. doi: 10.1016/j.jpainsymman.2005.01.011. PubMed 15907642 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2025; primary completion for Oct 2026, 12 months later.

Of 291 non-industry observational studies under Frailty, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 55. This study's planned 12 months is below that.

Counting every sponsor, half of 294 studies reached it within 29 months; a quarter within 12 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2025
First posted
May 1, 2025
StartEst.
Oct 1, 2025
Primary completionEst.
Oct 1, 2026
CompletionEst.
Oct 10, 2026
Last update
May 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06953570
Lead sponsor
Yongtao Sun
Responsible party
Yongtao Sun (Professor, Qianfoshan Hospital) — Sponsor-investigator
First posted
May 1, 2025
Start date
Oct 1, 2025 (estimated)
Primary completion
Oct 1, 2026 (estimated)
Completion
Oct 10, 2026 (estimated)
Last update
May 1, 2025

Study contacts

Yongtao Sun, Ph.D.
Contact
sunyongtao1979@163.com
18660795201
weiwei wang, M.A.
Contact
www18678653965@163.com
18678653965
Yongtao Sun, Ph.D.
study chair · Qianfoshan Hospital, The First Hospital affiliated of Shandong First Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion